Podcasts about Lung cancer

SHOWNOTES Apple Podcast Description: Episode Title: In this episode of All Talk Oncology, host Kenny Perkins (Your Cancer Guy) talks with Dr. Jeffrey Velotta, a thoracic surgeon practicing in Northern California, to discuss a growing and often misunderstood health crisis—lung cancer in people who have never smoked. While many people associate lung cancer primarily with smoking, Dr. Velotta explains that an alarming trend is emerging, particularly among Asian women who have never smoked. Despite California having one of the lowest smoking rates in the United States, the state continues to see some of the highest lung cancer incidence and mortality rates. Dr. Velotta breaks down the surprising risk factors behind this phenomenon, why many patients are being diagnosed at Stage IV, and what individuals can do to advocate for themselves when symptoms appear. This conversation is an essential listen for patients, caregivers, and anyone concerned about lung health—especially those who believe they are not at risk. In this episode, Dr. Castro discusses: Why lung cancer is increasing among non-smokers The alarming rise of lung cancer in Asian women Why many patients are diagnosed at Stage IV Key risk factors beyond smoking The importance of early detection and recognizing symptoms Why persistent cough should never be ignored When to request a chest X-ray or CT scan Why getting a second opinion is critical for cancer care How patients can find clinical trials and new treatment options Dr. Velotta also encourages patients to become active participants in their healthcare by asking tough questions, advocating for themselves, and seeking the best possible care. This episode provides vital insight into a growing public health issue and empowers patients with the knowledge needed to take action early. Don't forget to like, subscribe, and share to help spread awareness about lung cancer and empower patients with life-saving information. Immortalize your voice by being an ALL TALK ONCOLOGY GUEST! Just fill-out this FORM. Invite Kenny Perkins to Speak or Participate on your event. Just fill-out this FORM.   SOCIAL MEDIA LINKS: All Talk Oncology: Instagram & Facebook JOIN OUR FREE COMMUNITY: Facebook Community WEBSITE: www.alltalkoncology.com Hashtags:  #LungCancerAwareness #LungCancerInNonSmokers #ThoracicSurgery #CancerScreening #AllTalkOncology #YourCancerGuy #CancerEducation #CancerAdvocacy

In this episode of TOGA's Conversations in Lung Cancer Research, host A/Prof Gavin Wright sits down with a multidisciplinary panel of experts to tackle the critical and complex issue of smoking-related stigma in lung cancer. The conversation explores how social constructs and industry blame-shifting fuel psychological distress, create barriers to the National Lung Cancer Screening Program, and potentially compromise equitable patient care. The panel offers clinical, psychological, and biological perspectives on how the healthcare system can dismantle this stigma to improve patient outcomes and quality of life.  Host A/Prof Gavin Wright is a thoracic surgeon, director of Surgical Oncology at St. Vincent's Hospital, and the surgical representative on TOGA's scientific committee—is an esteemed panel of specialists leading the charge against lung cancer stigma. He is joined by Dr. Allison Black, an oncology consultant at the Royal Hobart Hospital who sub-specialises in gynecological and lung cancers; A/Prof Henry Marshall, a thoracic physician at the Prince Charles Hospital and the University of Queensland Thoracic Research Center; and Professor Suzanne Chambers, a health psychologist, psycho-oncology researcher, and Executive Dean of Health Sciences at the Australian Catholic University. Together, they bring a vital combination of surgical, oncological, respiratory, and psychological expertise to this crucial discussion.  00:00 Welcome and Acknowledgement 00:55 Meet the Panel 01:54 What Stigma Means 04:43 Tobacco Industry Blame 06:11 Why Screening Matters 08:44 Treatment Without Judgment 12:15 Fixing Stigma Systemwide 17:13 Equity and Access Gaps 18:35 Shared Decisions and Support 21:24 Quitting Without Shame 24:33 Language and Closing Takeaways 26:49 Episode Wrap Up ---------------Support TOGAThank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.---------------Connect with TOGAAttend an Event: https://thoraciconcology.org.au/events/Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/Follow UsLinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/X (Twitter): https://x.com/TOGAANZInstagram: https://www.instagram.com/togaanz/YouTube: https://www.youtube.com/@Thoracic_Oncology---------------Acknowledgement of CountryThe Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

In this podcast, Danny Nguyen from the Department of Medical Oncology & Therapeutics Research, City of Hope, Huntington Beach, CA, USA discusses clinical considerations for subcutaneous amivantamab dosing and administration, including premedications, prophylactic measures, dose modifications, management of adverse reactions, and switching between IV and SC amivantamab. This podcast is published open access in Targeted Oncology and is fully citeable. You can access the original published podcast article through the Targeted Oncology website and by using this link: https://link.springer.com/article/10.1007/s11523-026-01248-7. All conflicts of interest can be found online. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

Joanna Nathan, CEO and co-founder of Prana Surgical, adjunct professor at Rice University and a former MedTech investor who spent years at the J&J MedTech Center for Device Innovation before crossing over into building herself. Her company recently secured FDA clearance for the Prana System, a tissue-sparing platform rethinking how early stage lung cancer is diagnosed and treated.In this episode, Joanna shares the deeply personal story behind her move from investing back into operating, having lost her four year old son in 2021 and wanting proximity to patient impact rather than evaluating innovation from the sidelines. It is an honest and moving conversation about what actually drives someone to take on a decade-long mission.We get into what she learned watching hundreds of pitches from the investor seat, why a no is very often about portfolio construction and timing rather than the quality of your idea, and why a fundraising pitch is a vision document backed by evidence rather than a journal article. Joanna then breaks down the problem Prana is solving, why removing large portions of lung for a tiny early stage nodule is no longer justifiable and how the system is right-sized for the level of risk these smaller lesions present.We also explore the changing face of lung cancer, the rise of never smokers now approaching one in three patients, why the disease is getting younger and more female, the role of mobile screening in rural areas and where AI genuinely helps rather than replaces clinical judgement. Joanna closes with hard-won advice for anyone thinking about founding a company and why community is what carries you through.Timestamps[00:01:38] From Research to Investing to Building: The Path Back to Operating[00:03:33] Why a No From an Investor Is Rarely About Your Idea[00:05:29] Why a Pitch Is a Vision Document Not a Journal Article[00:07:16] The Problem With Early Stage Lung Cancer Surgery Today[00:09:22] The Rise of Never Smokers and a Disease That Is Changing Fast[00:11:03] Why Women Under 50 Now Face Higher Lung Cancer Rates[00:13:18] Getting Creative on Access: Mobile CT Screening in Rural Areas[00:17:21] AI in MedTech: Assisting Clinical Judgement Not Replacing It[00:19:22] How Houston Became an Unlikely MedTech Powerhouse[00:24:06] Who Should Not Become a Founder and the Decade-Long QuestionConnect with Joanna - ⁠linkedin.com/in/joannacnathan/Learn more about Prana Surgical - https://www.pranasurgical.com/Get in touch with Karandeep Badwal - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/in/karandeepbadwal/ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Follow Karandeep on YouTube - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/@KarandeepBadwal⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medical device training courses delivered by Karandeep through Bywater - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.bywater.co.uk/

Shira Boehler's family is full of doctors, and every one of them told her not to get the full-body MRI. She canceled the appointment repeatedly herself, until her husband rebooked it one time too many and she finally went.The scan found a 3.8 centimeter mass in her right lung and labeled it a minor finding, with a note to correlate with symptoms. She had none. She was running six miles a day, the picture of health, and had never smoked. A follow-up CT months later showed the mass had grown, and on the Monday she walked into a pulmonary specialist's office she was told she had an invasive adenocarcinoma. She told him it was probably an EMR error. One week later, surgeons removed half her right lung to treat her cancer.Samira Daswani, host of Patient from Hell and founder of Manta Cares, welcomes lung cancer survivor and bestselling author Shira Boehler for an eye-opening conversation on the part that comes after the story, which is why almost nobody in Shira's position gets caught this early. Screening guidelines currently cover people over 50 with a twenty-pack-per-year smoking history, and fewer than one in five of them actually get scanned, in part because the criteria require disclosing something patients are ashamed of. Shira has been working the problem from both ends since her treatment, negotiating cash prices at imaging centers down to a fraction of what she paid and funding new scans for people who can't cover them through the nonprofit organization she founded, Cancer Doesn't Care.In this episode, Samira and Shira discuss:Why lung cancer is often diagnosed too lateThe importance of early detection and low-dose CT screeningHow people who have never smoked can still develop lung cancerThe stigma surrounding lung cancer diagnosisCurrent lung cancer screening guidelinesInsurance coverage, healthcare access, policy reformHow artificial intelligence may improve cancer screeningWhy patient advocacy is becoming increasingly important in modern healthcareChapters00:00 Introduction01:00 The Full-Body Scan That Changed Everything03:32 Diagnosed With Lung Cancer Despite Having No Symptoms05:30 Access, Privilege & Why Early Detection Isn't Equal07:10 Building the Cancer Doesn't Care Foundation09:21 Why Lung Cancer Screening Needs to Change10:19 Breaking the Stigma Around Lung Cancer12:26 Who Actually Qualifies for Screening?14:23 Changing Public Perception Through Advocacy16:20 Why Patients Must Advocate for Themselves17:15 AI, False Positives & the Future of Cancer Screening20:27 Why Lung Cancer Is Often Diagnosed Too Late21:17 Stage 1 vs. Stage 4 Survival Rates23:25 Shira's Advice for Anyone Considering Lung Cancer ScreeningShira Kupperman Boehler is a finance professional, health advocate, bestselling author, and lung cancer survivor. Shira holds a degree in Molecular and Cell Biology from the University of California, Berkeley, and an MBA from New York University's Stern School of Business. Alongside her husband Adam, she has spent her career building and scaling multibillion-dollar healthcare businesses, developing deep relationships across health systems, payers, and policymakers.After being unexpectedly diagnosed with Stage 1B lung adenocarcinoma despite never smoking and having no symptoms, Shira founded Cancer Doesn't Care, a nonprofit dedicated to expanding access to life-saving lung cancer screening and reducing financial barriers to early detection. She is also the author of the bestselling memoir One Scan Saved My Life, with proceeds supporting patient screening initiatives.

In this episode of the STS Thinking Thoracic podcast, host Dr. Jeff Yang is joined by thoracic surgeons Dr. Seth Krantz and Dr. Christopher Seder, along with Harvard medical student Alexandra Potter, to discuss three landmark studies using the STS General Thoracic Surgery Database that are reshaping how lymph node evaluation is performed in lung cancer surgery. The panel explores current guidelines, quality standards, and how more comprehensive nodal evaluation can improve staging accuracy while maintaining patient safety. The discussion highlights national trends in surgical quality, the importance of surgeon-pathologist collaboration, and the future of personalized lymph node evaluation, including the potential role of emerging technologies such as radiomics, genomic markers, and AI.

In this episode of 'Conversations in Lung Cancer Research,' host A/Prof Mel Moore interviews Dr. Jazmin Eckhaus, a practising surgeon in the subspecialty of thoracic surgery, and specialising in minimally invasive thoracic surgery and pleural disease. Dr. Eckhaus discusses her extensive training and experience, groundbreaking work in robotic lung surgery, and her contributions to the development of the Binational Australian and New Zealand Thoracic Surgical Database. The conversation also explores Dr. Eckhaus' academic pursuits in clinical ethics at Oxford University and the practical implications for informed consent in surgical procedures. This episode provides an in-depth look into the evolving field of thoracic surgery, advancements in robotic technology, and the essential role of comprehensive data collection in improving patient outcomes. (00:00) Introduction and Acknowledgements (00:39) Meet Dr. Jazmin Eckhaus (01:52) Journey to Thoracic Surgery (04:57) Robotic Surgery Innovations (11:53) Thoracic Surgical Database (15:53) Clinical Ethics and Consent (26:19) Personal Interests and Conclusion Support TOGAThank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.---------------Connect with TOGAAttend an Event: https://thoraciconcology.org.au/events/Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/Follow UsLinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/X (Twitter): https://x.com/TOGAANZInstagram: https://www.instagram.com/togaanz/YouTube: https://www.youtube.com/@Thoracic_Oncology---------------Acknowledgement of CountryThe Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

This clip comes from Dr. Raj's series with My Care Friends. Watch the video here: https://youtu.be/IsnRE6EAygw?si=V0-HJYdIPYNccXC9 About Dr. Raj Dr. Raj Dasgupta is an ABIM Quadruple board-certified physician specializing in internal medicine, pulmonology, critical care, and sleep medicine. He is currently the Associate Program Director of Internal Medicine Residency at Huntington Health in Pasadena, California and an Associate Professor of Clinical Medicine for the University of California, Riverside School of Medicine (UCR). He previously practiced at the University of Southern California, where he is an associate professor of clinical medicine, assistant program director of the Internal Medicine Residency Program, and the associate program director of the Sleep Medicine Fellowship. Dr. Dasgupta is an active clinical researcher and has been teaching around the world for more than 20 years. More from Dr. Raj ⁠⁠⁠⁠The Dr. Raj Podcast⁠⁠⁠⁠ ⁠⁠⁠⁠Dr. Raj on Twitter⁠⁠⁠⁠ ⁠⁠⁠⁠Dr. Raj on Instagram⁠⁠⁠⁠ Want more board review content? ⁠⁠⁠⁠USMLE Step 1 Ad-Free Bundle⁠⁠⁠⁠ ⁠⁠⁠⁠Crush Step 1⁠⁠⁠⁠ ⁠⁠⁠⁠Step 2 Secrets⁠⁠⁠⁠ ⁠⁠⁠⁠Beyond the Pearls⁠⁠⁠⁠ ⁠⁠⁠⁠The Dr. Raj Podcast⁠⁠⁠⁠ ⁠⁠⁠⁠Beyond the Pearls Premium⁠⁠⁠⁠ ⁠⁠⁠⁠USMLE Step 3 Review⁠⁠⁠⁠ ⁠⁠⁠⁠MedPrepTGo Step 1 Questions⁠⁠⁠⁠ ⁠⁠⁠⁠MedPrepTGo Step 2 Questions⁠⁠⁠⁠ Follow MedPrepToGo ⁠⁠⁠⁠https://medpreptogo.com⁠⁠⁠⁠ ⁠⁠⁠⁠https://www.instagram.com/medpreptogo/⁠⁠⁠⁠ ⁠⁠⁠⁠https://www.linkedin.com/company/medpreptogo/⁠⁠⁠⁠ ⁠⁠⁠⁠https://www.facebook.com/MedPrepToGo/⁠⁠⁠⁠ ⁠⁠⁠⁠https://www.youtube.com/@MedPrepToGo⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

This week on "The Top Line," Fierce Healthcare and Life Sciences' editor-in-chief steps behind the microphone for a solo episode highlighting several of the biggest stories in biopharma. The episode covers GSK’s first lung cancer approval following its acquisition of Nuvalent, Axiom Biosciences’ unusual plan to list first in Hong Kong before pursuing a Nasdaq co-listing amid a resurgent biotech IPO market, and the U.S. House’s passage of legislation directing the FDA to update its animal testing rules. The episode also includes an update from the Fierce newsroom, including the arrival of a new Fierce Biotech staff writer, and a reflection on why human judgment, curiosity and original reporting matter more than ever. To learn more about the topics in this episode: GSK secures first lung cancer approval as FDA clears Jideytro in quick payoff from Nuvalent deal ‘There is always a first’: Why US biotech Axiom will begin its IPO journey in Hong Kong House passes bill directing FDA to update animal testing rules See omnystudio.com/listener for privacy information.

This episode is dedicated to Natalie's memory and to every patient navigating life with cancer.Natalie Brown's answer to "How are you?" was always simple:"I'm here."Diagnosed with stage 4 non-small cell lung cancer at just 33 years old, despite never smoking and having no family history of lung cancer, Natalie spent six years challenging assumptions about what lung cancer looks like.In this unforgettable conversation with host Samira Daswani, Natalie shares her journey through multiple rounds of chemotherapy, immunotherapy, failed clinical trials, and one of the rarest procedures in cancer medicine a bilateral double lung transplant. She also opens up about recurrence, chronic pain, advocacy, mental health, and why she believed every patient deserves to know all of their treatment options.Natalie has passed away. We are honored to share her story again in celebration of the courage, honesty, humor, and determination that defined her life. Her voice continues to educate, inspire, and advocate for patients everywhere.Whether you're living with cancer, supporting someone who is, or simply want to better understand the realities of serious illness, Natalie's message is one everyone should hear.In this episode you'll learn:What it's like to be diagnosed with stage 4 lung cancer at age 33Why non-smokers can develop lung cancerHow a rare double lung transplant became a treatment optionThe emotional reality of cancer recurrenceClinical trials, targeted therapies, and asking "What's next?"The importance of patient advocacy and second opinionsHow friends, family, therapy, and hope helped Natalie keep fightingWhy "Anyone with lungs can get lung cancer"Natalie's story reminds us that resilience isn't about pretending things aren't difficult—it's about continuing to move forward anyway.00:00 Introduction: Remembering Natalie Brown01:00 "I'm Here" — The phrase that defined Natalie02:00 Diagnosed with Stage 4 Lung Cancer at 3304:00 Four Chemotherapies & Failed Clinical Trials05:30 Discovering a Rare Double Lung Transplant10:40 Returning Home After Transplant11:45 Cancer Recurrence & New Treatment Options13:00 The Husband Who Helped Her Keep Fighting16:00 Facing Mortality with Honesty18:00 Making the Most of Time20:00 Living with Chronic Pain21:00 Becoming a Lung Cancer Advocate24:00 Learning to Ask for Help26:45 Advice for Newly Diagnosed Patients28:40 "Anyone With Lungs Can Get Lung Cancer"29:45 Why Patients Should Always Ask Questions31:00 Final ReflectionsAbout Patient From HellPatient From Hell is hosted by cancer survivor and founder Samira Daswani, who asks the questions most patients are too overwhelmed or too afraid to ask. The show brings together doctors, researchers, advocates, and survivors to reveal evidence-based answers for patients navigating the chaos of cancer.

Lung health specialists at Sarasota Memorial Health System have discovered a detection program that can catch lung cancer early – at Stage I or Stage II --when patients have the best chance of survival from the disease.

How could cellular therapies and cancer vaccines transform the future of treatment for ALK-positive lung cancer? Host Dr. Narjust Florez sits down with Dr. Vincent Lam and Dr. Carmen Mecca to explore the latest research, the science driving these innovative approaches, and what these advances could mean for patients and the future of precision oncology. Key Topics Covered: • ALK-positive lung cancer • Cellular Therapy • Vaccines Guests: Vincent Lam, MD Associate Professor of Oncology, Johns Hopkins University School of Medicine Director, Thoracic Oncology Clinical Research Program Sidney Kimmel Comprehensive Cancer Center Carmen Mecca. PhD Postdoctoral Fellow, Chiarle Lab Department of Pathology Boston Children's Hospital

Jonathan Villena-Vargas, MD, sits down with Erin Gillaspie, MD, to examine key findings from the American Society of Clinical Oncology (ASCO) Annual Meeting, including advances in targeted therapy, dual-pathway immunotherapy, artificial intelligence, and adaptive treatment strategies that are reshaping thoracic oncology.

HOST:  Hildy Grossman CO-HOST:  Jordan Rich GUESTS:   Joan H. Schiller, MD and Francine Jacobson, MD, MPH In 2021, the World Health Organization issued a stark warning: climate change is the single biggest health threat facing humanity. And yet, the public often perceives climate change as an abstract concept or a political debate, not a health problem. It's time to change this perception. Alarmingly, lung cancer deaths have surged by nearly 30% since 2007. Every year we experience accelerating heat waves, wildfires, droughts, and extreme weather events. Moreover, all these changes impact cancer occurrence and care. Our guests probe deeply into this serious problem, looking at causes and possible solutions.    Dr. Schiller explains how her global group, OUCH (Oncologists United for Climate and Health) fights back using education and advocating for policy change to protect cancer patients and us all from the dangers of climate change. Meanwhile, Dr. Jacobson supports increasing access to life-saving lung cancer screenings for underserved, high-risk communities. She suggests steps to accomplish this by expanding criteria for screenings. Are we ready to treat climate change and air pollution like the medical emergency it is? Tune in to uncover the link between our environment and cancer - and how we can fight back.

Editor's Summary by Linda Brubaker, MD, and Preeti Malani, MD, MSJ, Deputy Editors of JAMA, the Journal of the American Medical Association, for articles published from July 3-10, 2026.

Join Dr. Martin in today's episode of The Doctor Is In Podcast.  

When someone has a years-long, multiple pack history of smoking, they are recommended to undergo screening for lung cancer utilizing a technology known as low dose computed tomography or low dose CT. Yet only about 18% of those eligible for … Will a blood test compel more people to be screened for lung cancer? Elizabeth Tracey reports Read More »

Featuring perspectives from Ms Courtney Arn, Ms Jamie Carroll, Dr Edward B Garon, Dr Heather McArthur and Dr Kathleen N Moore, moderated by Dr Moore, including the following topics: Introduction (0:00) Overview of Antibody-Drug Conjugates (ADCs) (2:07) Current and Future Role of HER2-Targeted ADCs for Breast Cancer (6:23) Currently Available ADCs for Gynecologic Cancer Management (26:37) Currently Available ADCs for Lung Cancer Management (44:07) Current and Future Role of TROP2-Targeted ADCs for Metastatic Breast Cancer (56:55) Other ADCs That May Soon Reach the Clinic for Advanced Gynecologic Cancers (1:15:07) Promising Investigational Strategies Employing ADCs for Lung Cancer (1:25:01) NCPD information and select publications  

Radon gas is naturally occurring, invisible, odorless, and the leading cause of lung cancer in non-smokers. Nearly three-quarters of Iowa homes have tested high, and yet most Iowans have never tested their home, and many have never heard of radon. Joined by Maria Steele, retired nurse practitioner and lung cancer survivor, Dr. Richard Deming, medical director at MercyOne Richard Deming Cancer Center, and Juliann Van Liew, Polk County Health Department Director, we look at the radon problem in Iowa. We talk about what it is, why it's so pronounced in the state, what's being done about it, and how to limit exposure.

In this episode, we review the high-yield topic of ⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Lung Cancer⁠⁠⁠⁠⁠⁠ from the Oncology section at ⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠⁠Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets

Should you stop taking glucosamine based on a new study linking it to Alzheimer's? What's behind the spate of “Tai Chi Walking” social media posts? Undereye “festoons”—what to do about them? Are antibiotics the only treatment for SIBO? Vaping after smoking hikes risk for lung cancer.

Link to claim CME credit: https://bit.ly/4uRr3ir In this episode, Elizabeth Krueger, NP, and Sam Vafadar, DHSc, PA-C, discuss how they optimize first-line EGFR-targeted therapy for patients with EGFR-mutated NSCLC, including: First-line treatment options available for EGFR-mutated NSCLC and the clinical trials that resulted in their approval Adverse event identification and management Generalized strategies to support patient adherence to TKIs Get access to all of our new podcasts by subscribing to the Decera Clinical Education Podcast on Apple Podcasts, YouTube Music, or Spotify Presenters: Elizabeth Krueger, NP Center for Thoracic Cancers Mass General Brigham Cancer Institute Boston, Massachusetts Sam Vafadar, DHSc, PA-C Physician Associate Department of Thoracic Oncology H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. Christine Lovly and Dr. Vamsi Velcheti discuss practice-changing lung cancer data presented at the 2026 ASCO Annual Meeting, including key studies on squamous cell lung cancer, NSCLC, and SCLC. LINK TO FULL TRANSCRIPT

Eating your fruits and vegetables is one of the easiest ways to care for…

Send us Fan MailS4E5 The Oncology Journal Club Podcast The Oncology Journal Club team returns with Part 2 of its ASCO 2026 coverage, delivering a whirlwind tour through some of the most interesting studies presented across gastrointestinal, breast, lung, genitourinary, gynaecological, skin and haematological cancers.Craig Underhill, Kate Clarke and Christopher Jackson discuss emerging data on ctDNA-guided treatment strategies, exercise as adjuvant therapy, genomic testing in breast cancer, novel antibody-drug conjugates, immunotherapy advances, de-escalation studies and potential new standards of care. They also explore the growing role of precision medicine, evolving treatment sequencing strategies and the challenges facing the global oncology workforce.Along the way, expect the usual OJC banter, ASCO bingo, questionable drug pronunciations and a recurring tribute to Qantas pyjamas!The Oncology Journal Club Podcast is hosted by Professor Craig Underhill, Dr Kate Clarke and Professor Chris Jackson, and proudly produced by The Oncology NetworkVisit oncologynetwork.com.au for Show Notes, to send us Voice Notes and more information. And to download your bingo card if you'd like to play along with the team!

This episode of Lung Cancer Considered provide a preview of the upcoming IASLC 2026 World Conference on Lung Cancer in Seoul, South Korea this September. Key topics covered include WCLC26 highlights - Multidisciplinary, WCLC26 deadlines and information about Seoul. Guests: Myung-Ju Ahn, MD, PhD Distinguished Professor Section of Hematology-Oncology, Department of Medicine Hanyang University Medical Center, Hanyang University School of Medicine Seoul, Republic of Korea Vincent Wentao Fang, MD Professor, Department of Thoracic Surgery Shanghai East Hospital Tongji University Medical School Jiraporn Setakornnukul, MD, PhD Radiation Oncologist, Associate Professor Division of Radiation Oncology Department of Radiology Faculty of Medicine, Siriraj Hospital Mahidol University Bangkok, Thailand Yasushi Yatabe, MD, PhD Chief, Department of Diagnostic Pathology, National Cancer Center Hospital Chief, Division of Molecular Pathology, National Cancer Center Research Institute National Cancer Center Japan

Dr Bill Nelson talks to thoracic surgeon, Dr Stephen Yang, about the developments in lung cancer surgery that have resulted in more minimally invasive procedures and improved patient outcomes.

Host Dr. Erin Gillaspie is back with a new season of the popular Best of Lung Cancer Science video podcast series. In this episode, featuring Dr. Jonathan Spicer, they break down key takeaways from the European Lung Cancer Congress, including evolving surgical approaches and how biology, AI, and real-world data are reshaping lung cancer care.

Send us Fan MailLung cancer is the leading cause of cancer deaths worldwide — but new advancements in screening, diagnosis, and treatment are changing outcomes for patients every day.In this episode of The Cass Health Podcast, pulmonologist Dr. Sumit Mukherjee joins us to talk about:Why lung cancer is often found lateWho should consider screeningWhat symptoms to watch forThe stigma around smoking & screeningThe impacts of radon exposureFuture concerns for current vaping habitsWhy he's hopeful about the future of lung cancer careWhether you're a current or former smoker, have a family history of lung cancer, or simply want to better understand your risks, this episode offers practical, understandable information.

In Part 2 of the ASCO 2026 Highlights series, hosts Dr. Narjust Florez and Dr. Stephen Liu are joined by Dr. Julie Brahmer and Dr. Solange Peters to discuss some of the most notable immunotherapy advances presented at the 2026 ASCO Annual Meeting. The conversation explores emerging data for PD-1/VEGF and PD-L1/VEGF bispecific antibodies, the growing role of antibody-drug conjugates in combination with immunotherapy, and promising new strategies targeting KRAS-mutant lung cancers, highlighting how these approaches may reshape the future treatment landscape. Guests: Julie R. Brahmer, MD, MSc, FASCO, FAIO The Marilyn Meyerhoff Professor of Thoracic Oncology Co-Leader, Cancer Immunology Research Program Co-Director, Upper Aerodigestive Cancers Program Director, Johns Hopkins Kimmel Cancer Center, Bayview Campus Professor Solange Peters, MD, PhD Chair of Medical Oncology Director of Oncology Department - CHUV Lausanne University Hospital

In this episode, Dr Abbie Begnaud discusses the importance of lung cancer screening and evolving strategies to improve early detection among high-risk populations, including: Low-dose CT screening, which reduces lung cancer mortality by detecting cancers at earlier, more treatable stages Updated screening guidelines that have expanded eligibility Key challenges that impact screening participation, including awareness, access, and broader risk assessment Get access to all of our new podcasts by subscribing to the Decera Clinical Education [Oncology] Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenter: Abbie Begnaud, MD, FCCP Associate Professor of Medicine University of Minnesota Pulmonary, Critical Care, Allergy and Sleep Medicine Program Director, Interventional Pulmonology Fellowship University of Minnesota Health Lung Cancer Screening Program Link to full program:  Advancing the Early Detection of Lung Cancer: A Multipronged Educational Initiative to Elevate Evidence-Based Screening Practices | Decera Clinical Education Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of the Oncology Brothers podcast, we discussed challenging cases focused on metastatic non-small cell lung cancer (NSCLC) with common EGFR mutations. Joined by experts Dr. Shirish Gadgeel from the Emory University and Dr. Wade Iams from Tennessee Oncology, the discussion revolved around two real-life patient cases. The first case featured a 54-year-old gentleman with active tobacco use and diffusely metastatic NSCLC, including an isolated brain lesion. The panel explored treatment options, including single-agent osimertinib versus dual combinations of amivantamab-lazertinib and osimertinib-chemotherapy, emphasizing the importance of shared decision-making and considering co-mutations and patient demographics. In the second case, the conversation shifted to supportive care and managing side effects, particularly focusing on skin toxicity associated with amivantamab. The experts shared their proactive approaches to patient education and the significance of monitoring and adjusting treatment plans to enhance patient quality of life.   Key Points: In EGFR-mutated NSCLC with CNS metastases, treatment selection between single-agent osimertinib and combination amivantamab-lazertinib vs. osimertinib-chemotherapy requires individualized consideration of age, co-mutations, extent of disease, and patient preference rather than mutation status alone. Younger patients with CNS disease may benefit from more aggressive upfront combination therapy, while shared decision-making remains central to navigating the expanded efficacy versus increased toxicity trade-off. Dermatologic toxicities associated with amivantamab requires proactive management including supportive care regimen, early dose adjustments and close patient monitoring to maintain treatment continuity. Providing the best available upfront therapy in metastatic EGFR-mutated NSCLC is critical, as sequencing options become more limited at progression. Join us for an insightful discussion on the latest treatment algorithms, the importance of personalized care, and the evolving landscape of NSCLC management.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966   Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/   Don't forget to subscribe for more episodes featuring conference highlights and challenging cases in oncology! #EGFRMutated, #LungCancer, #ThoracicOncology, #PersonalizedMedicine, #OncologyBrothers

Welcome back to the Oncology Brothers podcast! In this episode, we were joined by Dr. Isabel Preeshagul from Memorial Sloan-Kettering to discuss the latest advancements in lung cancer presented at ASCO 2026. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ We dived into four key studies that could change clinical practice: LIBRETTO-432: exploring the promising event-free survival data with selpercatinib in RET-positive disease and its implications for adjuvant therapy. CROWN 7yr Update: seven-year progression-free survival results with lorlatinib in ALK-positive non-small cell lung cancer and the associated side effects. CHRYSALIS-2: exciting findings regarding amivantamab for atypical EGFR mutations and its potential to become the new standard of care. HARMONi-6: dual-headed drug ivonescimab combined with chemotherapy in metastatic squamous cell lung cancer and its intriguing results. We also touched on the importance of molecular testing for all patients, regardless of stage or histology, and highlighted the latest updates on tarlatamab in small cell lung cancer. Tune in for an insightful discussion that aims to keep our oncology community informed and engaged with the latest research and treatment options! Don't forget to like, subscribe, and check out our other episodes for more insights on oncology treatments, conference highlights, and FDA approvals. #ASCO2026, #LungCancer, #ALKPositive, #RETPositive, #OncologyBrothers

In this episode, Dr. Paul Wheatley-Price speaks to Dr. Ross Camidge, our guest in this increidbly unique episode of "Perspectives", sharing his leading clinical expertise on the treatment of EGFR-positive lung cancer as Director of the Thoracic Oncology at the University of Colorado Cancer Center. On the other hand, being diagnosed with the same disease himself at stage 4 in 2022, Dr. Camidge shares his perspective and journey from the patient lens, walking in the same shoes that he'd built his career upon. Don't miss this unique episode!

In this episode of Onc Now, Paolo Bironzo joins us to discuss the evolving landscape of thoracic oncology and the innovations transforming lung cancer care. From targeted therapies and immunotherapy selection to advances in mesothelioma treatment and molecular profiling, Bironzo shares insights into the challenges clinicians face today and the future of precision medicine. He also reflects on the importance of treatment de-escalation, the complexities of clinical trials, and offers advice for the next generation of oncologists. Timestamps:   00:00 – Introduction   00:51 – Inspiration Behind Thoracic Oncology   03:17 – Current Challenges in Lung Cancer   04:50 – Impact of Targeted Therapies   07:14 – Selecting Patients for Immunotherapy   08:04 – Advances in Mesothelioma Treatment   14:52 – Molecular Profiling in Thoracic Cancer   19:52 – Challenges in Lung Cancer Trials   22:05 – Predicting Immunotherapy Response Challenges   24:23 – Future of Precision Medicine   26:05 – Advice for Early-Career Oncologists   28:40 – Three Wishes for Cancer Therapy 

HOST:  Hildy Grossman CO-HOST:  Jordan Rich GUESTS: Kyle Concannon, MD, Samantha Murrell, Bianca Bye and Leah Phillips The face of lung cancer is changing. No longer viewed simply as a “smoker’s disease” that only impacts older adults, there is a rising and concerning trend of younger adults and non-smokers being diagnosed with advanced disease.  Our guests today have so much light to shine on this issue. In this powerhouse episode, we hear from Samantha Murrell, diagnosed with Stage 4 with a HER2 biomarker at age 37. She notes that her way of coping with her diagnosis was to learn everything possible about her disease. She tells how hope comes with new, cutting-edge drugs targeting HER2 because they allow her to live a full and active life.   Our guest, Leah Phillips, a mother of three young children, also was shocked by her diagnosis of Stage 4 lung cancer at 43. She tells how she joined Bianca Bye, who faced the advanced diagnosis and tragic loss of both parents, within months of each other, to lung cancer. Leah and Bianca joined forces to create the Young Lung Cancer Initiative. Oncologist, Dr. Kyle Concannon notes how these three resilient women are finding meaning in advocacy as they work to transform suffering into meaning by helping others. This is an unforgettable, action-driven look at hope, survival, and taking control.

Jim Brown is 58 years old and a 10+ year Stage 4 Lung Cancer Survivor from Olympia, Washington. Jim was a career firefighter and his cancer was determined to be service connected. His journey has included significant side effects from his treat including mental health and metabolic syndrome. Through fierce self advocacy and hard work he has been able to find a point of equanimity in his journey. He is still taking targeted therapy, and will for the rest of his life.   About Man Up To Cancer: Man Up To Cancer (MUTC) is a registered 501c3 nonprofit organization dedicated to inspiring men impacted by cancer to connect and avoid isolation throughout diagnosis, treatment, and survivorship. MUTC provides peer-to-peer support through 53 local chapters across the U.S. and Canada, a Chemocare Backpack Program that delivers comfort and encouragement to men in treatment, and the Gathering of Wolves, the world's largest annual retreat for men impacted by cancer. Through these programs, MUTC meets men where they are—emotionally, socially, and physically—offering community, purpose, and hope. www.manuptocancer.org ________ To learn more about the 10 Radical Remission Healing Factors, connect with a certified RR coach or join a virtual or in-person workshop visit www.radicalremission.com.   To learn more about Radical Remission health coaching with Liz or Karla, Click Here   Join our mailing list and you'll receive our free eBook, Kickstart Your Healing: 20 Radical Remission Tips, as a special thank you for joining. Subscribe Here   To watch Episode 1 of the Radical Remission Docuseries for free, visit our YouTube channel here. To purchase the full 10-episode Radical Remission Docuseries visit Hay House Online Learning. Follow us on Social Media: Facebook  Instagram YouTube ______ Our Sponsors: Connect & Thrive (CAT) is a heart-centered social impact company dedicated to supporting cancer previvors, patients, thrivers, and caregivers. CAT makes it easy for friends and family to help through intentional giving. Personalized KittyFunds™ and E-Gift Cards empower patients to begin their healing journeys by providing access to trusted integrative therapies and healthy living products not typically covered by insurance. Importantly, 100% of donations made to patients go directly to them for use in CAT's carefully curated Marketplace. By connecting patients with a supportive community and meaningful resources, CAT helps women move forward with confidence during treatment, recovery, and thrivership. CAT's mission is simple yet powerful: to help women CONNECT with a supportive community so they can truly THRIVE! “In the face of uncertainty, there is nothing wrong with hope.” ~O. Carl Simonton Visit www.connect-and-thrive.com Linkedin: https://www.linkedin.com/in/christine-anastos/ Facebook: https://www.facebook.com/CATconnectandthrive/ Instagram: https://www.instagram.com/connect_and_thrive/ _____ Nestled in the pristine, natural beauty of British Columbia, The Healing Oasis stands as Canada's first-of-its-kind cancer wellness retreat, where hope reignites and the body is empowered to heal. Here, our renowned naturopathic cancer expert, Dr. Sean Ceaser, designs a fully personalized protocol of advanced, non-toxic therapies—including high-dose IVs like mistletoe and vitamin C, cutting-edge hyperthermia, PEMF, oxygen therapy, red light, and more. Savor daily organic, cancer-fighting meals, rest deeply in serene cabins, immerse in restorative activities like forest walks and yoga, drink mineral-rich living water, and receive emotional support in a peaceful sanctuary that combines world-class care with profound nature immersion to reduce side effects, boost vitality, and spark radical healing. Your journey to feeling alive again begins today at thehealingoasis.ca. Learn More about The Healing Oasis: Website   Testimonials Video Overview

In recognition of National Women's Health Month, this episode of Thinking Thoracic analyzes the evolving landscape of female-specific lung cancer care. Co-hosts Dr. Erin Gillaspie and Dr. Jane Yanagawa sit down with guest Dr. Leah Backhus to discuss a critical disparity: lung cancer is the leading cause of cancer death among women, yet screening practices remain inequitable.    This timely episode moves beyond smoking history to examine the rise of lung cancer in never-smokers and Asian women. From the "stigma" of a diagnosis to innovative solutions like co-scheduling screenings with mammograms, providing a powerful call to action for more inclusive, biomarker-driven care. 

In this episode, pulmonologist, intensivist, and advanced bronchoscopist Huzaifah Salat joins Duane Manicini to unpack what's changing in lung cancer care, and why the biggest constraint in MedTech isn't the FDA, funding, or clinician adoption, but founders building for clinicians instead of with them. Huzaifah shares how robotic bronchoscopy, advanced imaging, and better CT quality are enabling diagnosis of tiny, moving lung nodules, and why the next wave may be non-invasive diagnostics like blood-based, saliva, or bronchial secretion testing. He offers an inside look at serving as a regional medical director and physician voice to the C-suite, where “no margin, no mission” meets patient-first priorities, and explains how diverse frontline perspectives, beyond physicians alone, shape products that truly fit real clinical workflows.Huzaifah Salat LinkedInDuane Mancini LinkedInProject Medtech WebsiteProject Medtech LinkedInThank you to our sponsors: Ward Law and JumpStart Inc.

Greek Mountain Tea is well-known in the Mediterranean region, with many traditional uses. Traditionally a tea, it can now be used as a supplement in a capsule! And don't miss the following topics that Terry will also discuss on this show: The Effects of the Keto Diet on Mental Health,  Nutrient of the Day: Quercetin,  Help for Aching Joints: Collagen,  Eating a Healthy Diet Increases Risk of Lung Cancer. Wait – WHAT?? New Study of Long COVID in Kids.

Only one in three eligible lung cancer patients receives the targeted therapy they should get.That is not a failure of science.It is a failure of delivery.After more than two decades of precision oncology, biopharma has never had better tools: cell and gene therapy, in vivo CAR-T, antibody-drug conjugates, AI-enabled diagnostics, organoids, multi-omics, and global clinical data.Yet too many breakthroughs still fail to reach the bedside.Patients fall through fragmented systems.Data does not move cleanly.Community oncologists are overloaded.Tests are missed, delayed, or misread.Promising assets die in quarterly portfolio reviews.And healthcare systems built for pills, tablets, and chronic disease management are now being asked to deliver personalized medicine at scale.In this SPARK20 highlight episode, Alasdair Milton, PhD, Principal at KPMG and leader of the firm's Precision & Advanced Therapies practice, explains why the future of biopharma will not be decided by science alone.It will be decided by translation.From lab bench to boardroom.From data to decisions.From treatment to prevention.Alasdair brings more than 20 years of experience across life sciences strategy, commercial due diligence, precision medicine, advanced therapies, cell and gene therapy, biopharma M&A, diagnostics, and global healthcare transformation.This conversation moves from the precision medicine delivery crisis to China's biotech acceleration, from AI and organoids to trapped pharma assets, from lifelong wellness to the one skill every future biotech leader needs:The ability to translate complex science into business strategy, capital allocation, and patient impact.What You'll Learn in 22 MinutesWhy only one third of eligible lung cancer patients receive targeted therapy(00:01:53)And why precision medicine still breaks in everyday clinical practice.Why science keeps compounding even when systems fail(00:04:33)Including in vivo CAR-T, functional cures, gene therapy, and antibody-drug conjugates.Why innovation does not move in a straight line(00:05:20)How technologies can look dead for years before suddenly changing the market.Why China's biotech speed matters(00:07:36)How AI, organoids, scale, and execution are changing the global innovation map.Why great science dies inside Big Pharma(00:09:20)And how deprioritized assets can become billion-dollar companies when externalized properly.Why the industry must move from sickness to lifelong wellness(00:10:03)Alasdair's vision for a more proactive, preventive, data-driven healthcare system.Why pharma needs better ways to rescue shelved assets(00:13:06)Including examples such as SpringWorks, Cerevel, and new models for unlocking trapped value.How a 400-person Scottish island shaped Alasdair's worldview(00:15:07)The personal story behind his resilience, discipline, and leadership style.Why careers and companies are never linear(00:17:19)What Alasdair learned after moving to Boston and losing his role within weeks.Why the future belongs to translators(00:20:06)The most valuable skill in biotech: explaining complex science to business leaders, investors, and boards.How to connect with Alasdair Milton and the KPMG Precision & Advanced Therapies team(00:21:47)Quotes to Carry With You

What is PD-L1, and why does it matter so much in your lung cancer treatment plan? Patient host Colette Smith talks with Dr. Julie Brahmer of Johns Hopkins University Hospital to demystify PD-L1 testing, immunotherapy decisions, and personalized lung cancer care. You'll learn: What PD-L1 is and how cancer cells use it as a "cloaking device" How Tumor Proportion Scores (TPS) from 0 to 100 guide treatment choices When immunotherapy alone works—and when chemotherapy should be added Why repeat biopsies matter for long-term survivors The most common side effects of immunotherapy and how they're managed When immunotherapy may not be the right option Key questions to ask your oncologist at every stage of treatment Why every patient should ask about clinical trials Whether you're newly diagnosed or navigating a treatment change, this conversation offers clarity, hope, and actionable guidance.  Get the full PD-L1 guide and download free patient resources: https://lcfamerica.org/about-lung-cancer/diagnosis/understand-pd-l1/ Heading to a doctor's appointment? Download LCFA's "Questions to Ask Your Care Team about PD-L1" PDF at lcfamerica.org. Learn more at lcfamerica.org. Guests: Dr. Julie Brahmer, Johns Hopkins University Hospital Colette Smith, Patient Host Show Notes - https://lcfamerica.org/wp-content/uploads/2026/05/LCFA-HWA-PD-L1-in-Lung-Cancer-Show-Notes.pdf  Transcript - https://lcfamerica.org/wp-content/uploads/2026/05/LCFA-HWA-PDL1-Transcript.pdf  YouTube - https://youtu.be/Ymff6MwaJTc  Subscribe to Hope With Answers: Living With Lung Cancer podcast for future episodes on your favorite listening platform.

In this episode, host Sylvie Legere sits down with Shira Kupperman Boehler and Dr. Kim Sandler to discuss the vital topic of early lung cancer detection. Having been diagnosed after a precautionary scan, non-smoker Shira shares her harrowing journey and advocates for change in diagnostic guidelines. Broadcasting from Wrigley Field emphasizes the importance of transforming how lung cancer is diagnosed, and how it is perceived by the medical community and public. Their conversation dives into the shortcomings of current screening guidelines and the urgent need for change to save more lives, especially for those who don't fall within the traditional risk categories. Through personal narratives and professional expertise, Dr. Sandler and Shira Kupperman Boehler share a holistic approach to detect lung cancer early by employing cutting-edge technologies and personalized medicine.  Act after listening: 1. Find out if you qualify for a free scan. If you're between 50–80 with a significant smoking history, you may be eligible for an annual low-dose CT scan — covered by Medicare and most private insurance. (Link in Resources below) 2. Ask your doctor even if you don't qualify. The current guidelines don't cover never-smokers — but that doesn't mean your risk is zero. At your next appointment, ask: "What is my personal lung cancer risk, and should I be screened?" Don't wait for symptoms. 3. Add your voice to change the guidelines. The screening criteria need to be expanded. Visit the Cancer Doesn't Care Foundation to learn how to advocate for policy change — and to share your own story if you have one. 4. Share this episode. The person who needs to hear this probably thinks they're fine. Send it to someone you love.  Guest Bios Shira Kupperman Boehler is a finance professional and health advocate with degrees in Molecular and Cell Biology from the University of California, Berkeley, and an MBA from New York University's Stern School of Business. A lifelong athlete and mother of four, she now channels her experience into raising awareness about early lung cancer detection and advancing conversations around prevention and policy. Shira and her family live in Tennessee, where she juggles life from her minivan with a coffee in one hand and a carpool schedule in the other.   Dr. Kim Lori Sandler -  Kim is a Nashville native who completed her undergraduate education at Emory University and both medical school and residency at Vanderbilt University. She trained as a cardiothoracic radiologist and is currently a Professor of Radiology and Radiological Sciences at Vanderbilt University Medical Center.  Dr. Kim is a clinician-scientist and serves as the Director of the Vanderbilt Lung Screening Program. She is a women's health advocate who is working to leverage the success of screening for breast cancer to improve enrollment of women in lung screening.  Her research also focuses on improving lung cancer risk prediction and early detection with the incorporation of machine learning and both imaging and blood-based biomarkers.  Resources & Links Visit Shira Kupperman Boehler's Website Order Shira's book ‘Cancer Doesn't Care' and learn more about Shira Boehler's campaign to change the national lung screening guidelines Take The American Lung Association's "Saved By The Scan" quiz Take the Lung Cancer Basics & Screening Eligibility Quiz from LUNGevity 

In a special edition of the This Week in Global Development podcast, Devex cofounder and Executive Vice President Alan Robbins sits down with Brazilian thoracic surgeon Dr. Ricardo Sales do Santos to discuss a revolutionary approach to tackling lung cancer in medically underserved communities in Brazil.   As the most lethal form of cancer globally, lung cancer often goes undetected until its final stages, but Dr. Santos and the Bristol Myers Squibb Foundation (are working to change that narrative through a combination of mobile technology and local capacity building. By bringing advanced CT scanning units directly into high-risk, low-income communities, they are catching tumors when they are small and potentially curable, fundamentally shifting the odds for thousands of patients.   The conversation also touches on the logistical and cultural hurdles of delivering specialized oncology care to remote areas. Dr. Santos highlights the importance of “bringing the clinic to the patient,” utilizing mobile CT units and telemedicine to bridge the gap in healthcare access. Beyond the technology, the success of the program relies heavily on empowering local health workers and community members to recognize early cancer warning signs and overcome the stigma associated with a cancer diagnosis. This approach not only improves individual health outcomes but also strengthens the broader healthcare system, offering a scalable model for global health initiatives.   To learn more about sustainable improvements in cancer care and get a compelling look at how local solutions can drive global change, listen to this special edition of This Week in Global Development. For more international development news, visit: http://www.devex.com Visit  Strengthening Care Systems — a series raising awareness of the scale of the global lung cancer burden and the systems-level changes required to address it: https://pages.devex.com/strengtheningcaresystems.html

Lung cancer is the leading cause of cancer deaths, yet funding to support patients can be hard to come by because of the stigma attached to it. While smoking is associated with lung cancer, many people who have never smoked are diagnosed with the disease. Racquel Williams talks with Ride Hard Breathe Easy, an organization that raises funds and awareness for lung cancer patients through community bike rides, as well as a social worker at Fox Chase Cancer Center and a woman who is on her fourth battle with the disease, to understand how we can support lung cancer patients and how to get screened. Get involved or learn more about Ride Hard Breathe Easy at www.rhbe.org. Then, on Shara in the City, Shara is heading out of the city to join the circus! She gets a behind-the-scenes sneak peek at the Philly-area premiere of Cirque du Soleil's “Luzia,” at the Greater Philadelphia Expo Center in Oaks now through June 7. Tickets to “Luzia” are available at www.cirquedusoleil.com.

In this episode of the Oncology Brothers podcast, we dived into the world of anti-EGFR therapies in non-small cell lung cancer (NSCLC). Joined by Dr. Joshua Sabari from NYU Langone Health and Dr. Azam Farooqui from Ironwood Cancer and Research Center, we discussed the latest advancements in treatment options, including the use of osimertinib, afatinib, and the combination therapy of amivantamab and lazertinib. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Key topics include: The role of afatinib in treating uncommon EGFR mutations and its associated toxicities The well-tolerated profile of osimertinib and its common side effects, including rash, diarrhea, and the rare risk of pneumonitis Insights into the combination therapy of amivantamab and lazertinib, including management of skin toxicity and the importance of prophylactic anticoagulation to mitigate VTE risks The episode emphasized the importance of maintaining quality of life for patients while ensuring they can stay on effective therapies for longer periods. Tune in for valuable clinical pearls and strategies to optimize patient care in the community setting. Don't forget to like, subscribe, and check out our other episodes for more insights on treatment algorithms and conference highlights! #LungCancer, #NSCLC, #EGFR, #TargetedTherapy, #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the exciting world of metastatic non-small cell lung cancer (NSCLC) with a focus on targeted mutations in the frontline setting. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ We were joined by Dr. Eric Singhi from MD Anderson Cancer Center, to discuss the latest advancements in treatment options, including: Common EGFR mutations and the benefits of combination therapies over single-agent osimertinib. The role of CNS involvement in treatment decisions and the importance of patient-centered care. Strategies for managing disease progression and the significance of re-biopsy. Insights into ALK-positive disease, including the efficacy of lorlatinib and alectinib. The latest developments in treating rare mutations like NTRK, MET, RET, and HER2. With a wealth of clinical data and practical insights, this episode is packed with valuable information for oncologists and healthcare professionals. Tune in to learn how to navigate the complexities of NSCLC treatment and improve patient outcomes. Don't forget to subscribe for more discussions on oncology topics and share your thoughts in the comments below! #LungCancer, #TargetedTherapy, #PrecisionMedicine, #NGS, #OncologyBrothers

"Skin reactions, such as redness, dryness, and just irritation of the skin, can occur. Since we're irradiating the lung, we can also cause a cough, and that's due to the inflammation from the radiation. Patients can also get esophagitis if the tumor that we're treating is close to the midline of the chest near the esophagus. And probably the most common side effect that we see is fatigue," ONS member Amy MacRostie, RN, OCN®, radiation oncology nurse at St. Charles Cancer Center in Bend, OR, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about radiation side effects in lung cancer. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.25 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by May 8, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the side effects of radiation to treat lung cancer. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 369: Lung Cancer Survivorship Considerations for Nurses Episode 363: Lung Cancer Treatment Considerations for Nurses Episode 359: Lung Cancer Screening, Early Detection, and Disparities Episode 313: Cancer Symptom Management Basics: Other Pulmonary Complications Episode 295: Cancer Symptom Management Basics: Pulmonary Embolism, Pneumonitis, and Pleural Effusion ONS Voice article: Highly Localized, Precision Radiation Therapies Require Nurses to Drive Care Coordination, Patient Education ONS book: Manual for Radiation Oncology Nursing Practice and Education (fifth edition) ONS courses: ONS/ONCC® Radiation Therapy Certificate™ ONS ROCN™ Certification Review™ ONS Radiation Learning Library ONS Guidelines™ and Symptom Intervention Resources National Comprehensive Cancer Network LUNGevity Foundation Inspire Lung Cancer Survivors Community To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "The types of radiation that can be used are external beam radiation and stereotactic body radiation treatment, or SBRT. External beam radiation is often used in combination with other treatment modalities, like chemotherapy, immunotherapy, and targeted therapy, to treat these cancers. And SBRT is usually done solo, and it's a highly precise treatment for inoperable or early-stage lung cancers." TS 1:52 "[Physicians and] providers can also help prevent side effects by reducing the dose to the heart and reducing the dose to the good lung tissue, if you will, as much as they possibly can. And this is done using intensity-modulated techniques, or IMRT. And that's where the linear accelerator sculpts the radiation beams conforming to the shape of the tumor itself." TS 6:37 "I think overall cancer treatment can lead to decreased libido and decreased sexual interest. Depression and fear can definitely play a role in this. And with lung radiation, specifically, fatigue and possibly shortness of breath with the exertion may decrease sexual interest. Nurses and providers should support the patient in their desire or lack thereof in sexual activities. We should have open discussions … and these can take place with patients about intimacy and how that can be approached in a different way that can accommodate for the side effects that the patients might be experiencing." TS 8:57 "Post-radiation scans will be abnormal. Post-radiation imaging can be misread as a progression of disease or residual disease. And I tell patients, 'Don't panic. Talk to your radiation oncologist so they can read the imaging themselves and interpret the results.' Oftentimes what's read as progression is radiation treatment sequela of scarring or fibrosis." TS 11:25

I've been a fan of actress and bestselling author Annabelle Gurwitch since I first read You Say Tomato, I Say Shut Up. I've interviewed her on my podcast about her last book You're Leaving When? and then got lucky enough to publish her new book, The End of My Life is Killing Me through Zibby Publishing — which has now been on the USA Today bestseller list for two weeks! You might have seen Annabelle lately because she has been all over the media with shout-outs from and interviews with Bill Maher, Drew Barrymore, Terry Gross at NPR, and Jenna Fischer. The book is hilarious and heartbreaking, fast-paced, thought-provoking, and a must-read. Hear from Annabelle and me at Totally Booked: Live in New York. ** Check out the Z.I.P. membership program—Zibby's Important People! As a Z.I.P., you'll get exclusive essays, special author access, discounts at Zibby's Bookshop, and more. Head to zibbyowens.com to subscribe or upgrade and become a Z.I.P. today!** Follow @totallybookedwithzibby on Instagram for more about today's episode. (Music by Morning Moon Music. Sound editing by TexturesSound. To inquire about advertising, please contact allie.gallo@acast.com.) Hosted on Acast. See acast.com/privacy for more information.